Policy announcement

FDA Puts Alzheimer’s Prevention on the Trial Agenda
The FDA has launched a cross-centre neuroscience initiative whose first focus is Alzheimer’s prevention. It will examine whom prevention trials should enroll, what outcomes they should measure and what evidence can support a prevention claim.

Ebola’s Vaccine Trial Enters New Territory

Barbados Made HIV Prevention Work

One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.

Food Safety Gets A Political Upgrade

Dengue Policy Goes Regional

ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote

Europe wants to catch cardiovascular risk before the first event

Raw Milk Cheese Triggered A National

Europe Is Moving to Ban Red Yeast Rice Monacolins. Can Bergamot Fill the Gap?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
